BioLife Solutions (BLFS) Misses Q3 EPS by 7c; Offers FY22 Revenue Guidance
Tweet
Share
E-mailGet Alerts BLFS Hot Sheet
Price: $28.18 -0.18%
EPS Growth %: +109.1%
Financial Fact:
Research and development: 496.87K
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: +109.1%
Financial Fact:
Research and development: 496.87K
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
BioLife Solutions (NASDAQ: BLFS) reported Q3 EPS of ($0.23), $0.07 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $40.7 million versus the consensus estimate of $42.02 million.
GUIDANCE:
BioLife Solutions sees FY2022 revenue of $160-164 million, versus the consensus of $163.4 million.
For earnings history and earnings-related data on BioLife Solutions (BLFS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
